非小细胞肺癌患者血清IL-17和VEGF含量的检测及其临床意义

目的检测非小细胞肺癌non—smallcelllungcancer，NSCLC）患者血清中自细胞介素17（interleukin．17，IL．17）和血管内皮生长因子vascularendothelialgrowthfactor，VEGF）的含量并分析其临床意义。方法采用双抗体夹心酶联免疫吸附法（ABC．ELISA）检测52例NSCLC患者术前血清和26名健康体检者血清中IL-17和VEGF的水平，比较两组血清中IL-17和VEGF含量水平的差异，并分析其与临床病理特征的关系。结果52例NSCLC血清中IL-17和VEGF的含量均明显高于26名健康志愿者（P=0．000）。NSCLC患者血清中IL-17和VEGF的含量呈负相关（r=-0．88，P=0．000）。NSCLC患者血清中IL-17的水平与吸烟状态、病理类型和临床分期相关，其中吸烟人群高于非吸烟人群（P=O．048），鳞癌高于腺癌（P=0．001），随着临床分期的增加，IL-17的水平逐渐降低。NSCLC患者血清中VEGF的水平与分化程度、临床分期相关，其中低分化患者高于中高分化者（P=0．000），且VEGF的水平随临床分期的增加而逐渐升高。结论NSCLC患者血清中IL-17和VEGF的水平均升高，两者均与临床病理特征密切相关，检测血清中IL-17和VEGF的水平对判断NSCLC患者的疾病状态有一定的参考价值。

Detection and clinical significance of serum levels of IL-17 and VEGF in patients with NSCLC

Objective To detect serum levels of IL-17 and VEGF in patients with non-small cell lung cancer（NSCLC ） and assess their clinical significance. Methods Serum levels of IL-17 and VEGF were determined in 52 NSCLC patients and 26 healthy controls using avidin-biotin complex ELISA.The levels as well as clinicopathological features were compared between the two groups. Results Serum levels of both IL-17 and VEGF levels were significantly higher in patients than in controls （P=0.OO0）.In NSCLC patients, serum IL-17 negatively correlated with VEGF expression （r=-0.88 ,P=0.000）.IL-17 expression was higher in smokers than non-smokers（P=O.048） and higher in squamous cell carcinoma patients than in adenocarcinoma patients（P=0.O01 ）.IL-17 concentration decreased and VEGF concentration increased with increasing NSCLC grade.Serum VEGF level was significantly higher in patients with poorly differentiated tumors than in those with well-differentiated ones （P=O.000）. Conclusions Serum levels of IL-17 and VEGF were significantly elevated in NSCLC patients and were strongly associated with clinicopathological features. Therefore, assaying IL-17 and VEGF may be useful for evaluating the prognosis of NSCLC patients.